
CURRICULUM VITAE

LARISA HUMMA CAVALLARI

March 2017

PERSONAL DATA

Office Address: Department of Pharmacotherapy and Translational Research
University of Florida, College of Pharmacy
PO Box 100486
1600 SW Archer Rd, Rm PG22 (for overnight deliveries)
Gainesville, FL 32610-0486

E-mail: lcavallari@cop.ufl.edu

Telephone: Office - (352) 273-8245
Fax - (352) 273-6485

EDUCATION

1986-1989 Pre-pharmacy
Georgia Southern University, Statesboro, Georgia

1989-1991 Bachelor of Science in Pharmacy, *Summa Cum Laude*
University of Georgia, Athens, Georgia

1995-1997 Doctor of Pharmacy
University of Georgia, Augusta, Georgia

POST-DOCTORAL TRAINING

1997-1998 *Pharmacy Practice Residency*
Veterans Affairs Medical Center, Memphis, Tennessee

1998-2000 *Cardiovascular Pharmacogenomics Research Fellowship*
The University of Florida, Gainesville, Florida

LICENSURE AND BOARD CERTIFICATION

Licensure: Georgia License No. 16872 (Issued 1991)

Board Certification: Board Certified Pharmacotherapy Specialist
No. 299166, Effective December 31, 1999

PROFESSIONAL APPOINTMENTS

01/2001 – 07/2009	Assistant Professor, Department of Pharmacy Practice University of Illinois at Chicago, Chicago, Illinois
08/2009 – 03/2014	Associate Professor, Department of Pharmacy Practice University of Illinois at Chicago, Chicago, Illinois
08/2010 – 03/2014	Adjunct Associate Professor Department of Biopharmaceutical Sciences University of Illinois at Chicago, Chicago, Illinois
04/2011 – 03/2014	Faculty, Institute of Human Genetics University of Illinois at Chicago, Chicago, Illinois
08/2012 – 03/2014	Faculty, Honors College University of Illinois at Chicago, Chicago, Illinois
10/2013 – 03/2014	Faculty, Center for Pharmacoepidemiology & Pharmaco-economic Research, University of Illinois at Chicago, Chicago, Illinois
04/2014 – present	Associate Professor, Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida
04/2014 – present	Director, Center for Pharmacogenomics, University of Florida
08/2014 – present	Faculty, Graduate School, University of Florida
12/2014 – present	Member, Genetics Institute, University of Florida
02/2015 – present	Associate Chair, Department of Pharmacotherapy and Translational Research, University of Florida
10/2015 – present	Member, University of Florida Health Cancer Center

PROFESSIONAL EXPERIENCE

08/1991 – 12/1992	Community Pharmacist, Phar-Mor Pharmacy, Stone Mountain, GA
01/1993 – 07/1994	Community Pharmacist, Eckerd Drugs, Lithonia, GA
07/1994 – 08/1995	Community Pharmacist, Eckerd Drugs, Savannah, GA
09/1995 – 06/1997	Staff Pharmacist, Eckerd Drugs, Augusta, GA
07/1997 – 06/1998	Clinical Pharmacist, VA Medical Center, Memphis, TN
07/1998 – 12/2000	Clinical Pharmacist, Heart Failure Clinic, Shands Hospital at The University of Florida, Gainesville, FL
07/2000 – 12/2000	Staff Pharmacist, VA Medical Center, Gainesville, FL
03/2001 – 03/2003	Clinical Pharmacist, Cardiology / Critical Care Unit University of Illinois Hospital & Health Sciences System, Chicago
01/2004 – 08/2012	Clinical Pharmacist, Antithrombosis Clinic, University of Illinois Hospital & Health Sciences System, Chicago
08/2012 – 03/2014	Co-Director, Warfarin Genetics Service, University of Illinois Hospital & Health Sciences System, Chicago, IL

05/15/2014 - present Associate Director, University of Florida Personalized Medicine Program

PROFESSIONAL AFFILIATIONS

American Association of Colleges of Pharmacy, 2001 to 2008
American College of Clinical Pharmacy, 1997 to present
American Heart Association, 2003 to 2008, 2011 to present
American College of Cardiology, 2012 to present
American Society of Clinical Pharmacology and Therapeutics, 2004 to present
Heart Failure Society of America, 1999 to 2012
Rho Chi Pharmacy Honor Society, 1990 to present
Pharmacogenetic Research Network, Affiliate member, 2009 to present
International Warfarin Pharmacogenetics Consortium (IWPC), 2008 to present
IWPC–Genome Wide Association Studies, 2011 to 2014

RESEARCH GRANTS

Current

Source: Canon Biosciences
Title: "Development and analytic validation of a customized pharmacogenomics panel"
Time Period: June 1, 2016 through April 30, 2017
Role: PI, 0.6 calendar months

Source: NIH/NHGRI (U01 HG 007269)
Title: "Genomic Medicine Implementation: The Personalized Medicine Program (PMP)"
Time Period: June 16, 2014 through May 30, 2017
Role: Co-Investigator, 3.0 calendar months (PI, Julie Johnson)

Source: U01-FD005235
Title: "Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs"
Time Period: September 1, 2014 through August 31, 2017
Role: MPI, 3.6 calendar months (Larisa Cavallari, Julie Johnson)

Source: Administrative Supplement to NIH/NHGRI (U01 HG 007269)
Title: "Genomic Medicine Implementation: The PMP"
Time Period: June 16, 2015 through May 30, 2017
Role: Co-Investigator, In kind (PI, Julie Johnson)

Source: Administrative Supplement to NIH/NHGRI (U01 HG 007269)
Title: "Genomic Medicine Implementation: The PMP"
Time Period: June 16, 2014 through April 30, 2016
Role: Co-Investigator, 0.6 calendar months (PI, Julie Johnson)

Source: NIH/NCATs (TR-14-009 1U54TR001347)
NIH/NCATs
Title: Together: Transforming and Translating Discovery to Improve Health
Time Period: 07/2015-06/2020
Role: Co-Investigator, 1.2 calendar months (PI, Nelson)

Source: University of Florida Clinical and Translational Science Institute Clinical Pilot Award
Title: "Integrating Pharmacogenomic Testing into a Child Psychiatry Clinic"
Time Period: July 2016 through June 2017
Role: Co-Investigator, 0.6 calendar months (PI, Carol Mathews)

Completed

Source: American College of Clinical Pharmacy Research Institute
Title: "Merck and Company Cardiovascular Fellowship"
Time Period: Accepted, then declined when AFPE fellowship (below) awarded.
Role: Fellow (Preceptor: Julie Johnson)

Source: American Foundation for Pharmaceutical Education
Title: "AFPE Clinical Pharmacy Post-Pharm.D. Fellowship in the Biomedical Research Sciences"
Time Period: July 1999 to June 2001
Role: Fellow (Preceptor: Julie Johnson)

Source: University of Illinois at Chicago Campus Research Board
Title: "Genetic Polymorphisms and Post-Infarction Remodeling"
Time Period: July 2001 to June 2002
Role: Principal Investigator (20% effort)

Source: American Foundation for Pharmaceutical Education
Title: "2002 AFPE Gateway Research Scholarship" – Awardee: Elizabeth Zhong, Pharm.D. student
Time Period: June 1, 2002 through May 31, 2003
Role: Preceptor (Mentor)

Source: University of Illinois at Chicago Campus Research Board
Title: "Cytochrome P450 2C9 Genotype and Phenotype in Cancer"
Time Period: June 1, 2003 through May 31, 2004
Role: Co-Investigator (PI, Stacy S. Shord)

Source: American Heart Association, Midwest Affiliate Scientist Development Grant
Title: "Angiotensinogen Genotype and Spironolactone Response"
Time Period: July 1, 2003 through June 30, 2006
Role: Principal Investigator (30% effort)

Source: American Foundation for Pharmaceutical Education; 2003-2004 American Association of Colleges of Pharmacy New Investigators Program
Title: "Influence of Vitamin K Reductase Genotype on Warfarin Dose Requirements"
Time Period: December 1, 2003 through December 1, 2004
Role: Principal Investigator (10% effort)

Source: American Health Assistance Foundation, National Heart Foundation
Title: "Cyclooxygenase-1 Genotype and Aspirin Response in Stroke"
Time Period: April 1, 2004 through March 31, 2006
Role: Principal Investigator (20% effort)

Source: American College of Clinical Pharmacy, Frontier Research Award
Title: "Mineralocorticoid Receptor Genotype and Potassium Response to Spironolactone"
Time Period: October 1, 2006 through September 30, 2007
Role: Principal Investigator (10% effort)

Source: University of Illinois at Chicago, Clinical and Translational Pilot Grant Program
Title: "Effects of Cytochrome P450 2D6 Genotype on Pain Management with Codeine in Sickle Cell Disease"
Time Period: January 1, 2007 through December 31, 2007
Role: Co-Investigator (10% effort, PI, Stacy S. Shord)

Source: University of Illinois at Chicago, College of Pharmacy, Hans Vahlteich Research Award
Title: "Genetic Determinants of Warfarin Dose Requirements in African Americans"
Time Period: October 2007 through September 2009
Role: Principal Investigator (20% effort)

Source: Osmetech Molecular Diagnostics
Title: "African American Sample Genotyping Study"
Time Period: June 1, 2008 through May 31, 2009
Role: Principal Investigator

Source: NIH, National Institute on Aging R03 (AG033381-01)
Title: "Genetic Determinants of Aldosterone Escape in Heart Failure"
Time Period: September 30, 2008 through August 31, 2010
Role: Principal Investigator (5% effort)

Source: American Heart Association, Midwest Affiliate Spring 2010 Clinical Research Program Award (10CRP3740026)
Title: "Clinical Studies of Novel Genetic Variation Affecting Warfarin Dose in African Americans"
Time Period: July 1, 2010 through June 30, 2011 (Returned with NIH R21 awarded)
Role: Co-Investigator (5% effort; PI, Minoli Perera)

Source: American Heart Association, Midwest Affiliate Spring 2010 Grant-In-Aid (10GRNT3750024)
Title: "Functional and Clinical Significance of the *CYP2C9*8* allele"
Time Period: August 1, 2010 through July 31, 2012
Role: Principal Investigator (5% effort)

Source: University of Illinois at Chicago Office of the Vice Chancellor for Research Areas of Excellence Program
Title: "Feasibility of an NIH Pharmacogenomics Research Network grant application"
Time Period: January 15, 2012 through January 14, 2013
Role: Co-Principal Investigator (5% effort)

Source: American Society of Health-System Pharmacists Foundation Pharmacy Resident Practice-Based Research Grant (10-RES-608) – Awardee: Adam Bress, Pharm.D.
Project: The Effect of Race and Genetic Variants on Diuretic Requirements in Patients with Systolic Heart Failure
Time Period: January 1, 2011 through December 31, 2012

Role: Mentor (5% effort)

Source: NIH, NHLBI R21 (HL106097)

Title: "Comprehensive Studies of Novel SNPs Affecting Warfarin Dose in African Americans"

Time Period: July 1, 2011 through June 30, 2013 (no cost extension to June 30, 2014)

Role: Co-Investigator (5% effort; PI, Minoli Perera, University of Chicago)

Source: University of Illinois at Chicago Office of the Vice Chancellor for Research Areas of Excellence Award

Title: "Development of an NIH Pharmacogenomics Research Network site grant application"

Time Period: February 1, 2012 through July 31, 2014

Role: Co-PI (5% effort with Julio Duarte)

Source: University of Illinois Hospital & Health Sciences System (UI-Health) Office of the Vice President for Health Affairs

Title: "Implementation of Warfarin Genetics at UI-Health"

Time Period: August 15, 2012 through August 15, 2014

Role: Principal Investigator (40% effort, In-kind)

Source: University of Illinois at Chicago Office of the Vice Chancellor for Research Areas of Excellence Award

Title: "Impact of Genetic Ancestry on Heart Failure Phenotype and Drug Response"

Time Period: February 1, 2012 through January 31, 2014

Role: Principal Investigator (10% effort)

Source: University of Florida Clinical and Translational Science Institute Clinical Pilot Award

Title: "Investigating the Impact of the *CYP2C19*17* Allele on Voriconazole Exposure in Patients with Invasive Fungal Infections"

Time Period: February 2015 through January 2016

Role: Mentor (Awardee: Issam Hamadeh)

Source: Mallinckrodt Pharmaceuticals

Title: 2015 Mallinckrodt Research Fellowship Award

Time Period: September 1, 2015 through August 30, 2016

Role: Mentor (Awardee: Scott Mosley)

PUBLICATIONS

Original Research

1. **(Cavallari) Humma LM**, Farmerie WG, Wallace MR, Johnson JA. Sequencing of β_2 -adrenoceptor gene PCR products using Taq BigDye-Terminator chemistry results in inaccurate base-calling. *BioTechniques* 2000;29(5):962-964, 966, 968. PMID 11084855.
2. Wang J, Mougey EB, David CJ, **(Cavallari) Humma LM**, Johnson JA, Lima JJ, Sylvester JE. Determination of human β_2 -adrenoceptor haplotypes by denaturation selective amplification and subtractive genotyping. *Am J Pharmacogenomics* 2001;1(4):315-322. PMID 12083963.

3. **(Cavallari) Humma LM**, Puckett BJ, Richardson HE, Terra SG, Andrisin TE, Lejeune BL, Wallace MR, Lewis JF, McNamara DM, Picoult-Newbert L, Pepine CJ, Johnson JA. Effects of β_1 -adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. *Am J Cardiol* 2001;88(9):1034-1037. PMID 11704005.
4. **(Cavallari) Humma LM**, Richardson HE, Lewis JF, McGorray, SP, Pepine CJ, Johnson JA. Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of β -blocker withdrawal: A Report from the Women's Ischemic Syndrome Evaluation Study. *Pharmacotherapy* 2002;22(8):939-946. PMID 12173796.
5. Andrisin TE, **(Cavallari) Humma LM**, Johnson JA. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. *Pharmacotherapy* 2002;22(8):954-960. PMID 12173798.
6. **Cavallari LH**, Fashingbauer LA, Beitelshees AL, Groo VL, Southworth MR, Viana MAG, Williams RE, Dunlap SH. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. *Pharmacotherapy* 2004;24(6):750-756. PMID 15222665.
7. Aquilante CL, **(Cavallari) Humma LM**, Yarandi HN, Andrisin TE, Lewis JF, Hamilton KK, Johnson JA. Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography. *Am J Cardiol* 2004;94(4):535-538. PMID 15325950.
8. Terra SG, McGorray SP, Wu R, McNamara DM, **Cavallari LH**, Walker JR, Wallace MR, Johnson BD, Bairey Merz CN, Sopko G, Pepine CJ, Johnson JA. Association between β -adrenergic receptor polymorphisms and their G-protein coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. *Int J Obes (Lond)* 2005;29(7):746-754. PMID 15917856.
9. **Cavallari LH**, Helgason CM, Brace LD, Viana, MA, Nutescu EA. Sex differences in the antiplatelet effect of aspirin after stroke. *Ann Pharmacother* 2006;40(5):812-817. PMID 16608908.
10. **Cavallari LH**, Groo VL, Momary KM, Fontana D, Viana MAG, Vaitkus P. Racial difference in potassium response to spironolactone in heart failure. *Congest Heart Fail* 2006;12(4):200-205. PMID 16894278.
11. **Cavallari LH**, Momary KM, Groo VL, Viana MA, Camp JR, Stamos TD. Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. *Pharmacotherapy* 2007;27(6):801-812. PMID 17542763.
12. **Cavallari LH**, Groo VL, Momary KM, Stamos TD, Vaitkus PT. Markers of cardiac collagen turnover are similar in patients with mild and more severe symptoms of heart failure. *Congest Heart Fail* 2007;13(5):275-279. PMID 17917494.
13. Momary KM, Shapiro NL, Viana MAG, Nutescu EA, Helgason CM, **Cavallari LH**. Factors influencing warfarin dose requirements in African Americans. *Pharmacogenomics* 2007;8(11):1535-1544. PMID 18034618.

14. Shord SS, **Cavallari LH**, Viana MAG, Momary K, Neceskas J, Molokie RE, Deyo K, Patel SR. Cytochrome P450 2C9 mediated metabolism in people with and without cancer. *Internat J Clin Pharmacol Ther* 2008;46(7):365-374. PMID 18793590.
15. Wang D, Chen H, Momary KM, **Cavallari LH**, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (*VKORC1*) affects gene expression and warfarin dose requirement. *Blood* 2008;112(4):1013-1021. PMID 18523153. PMCID: PMC2515137
16. **Cavallari LH**, Fashingbauer LA, Camp JR, King ST, Geenen DL. Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. *J Renin Angiotensin Aldosterone Syst* 2008;9(3):146-153. PMID 18957385.
17. Aquilante CL, Yarandi HN, **Cavallari LH**, Andrisin TE, Terra SG, Lewis JF, Hamilton KK, Johnson JA. Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. *Pharmacogenomics J* 2008;8(6):408-415. PMID 18253135.
18. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA on behalf of the International Warfarin Pharmacogenetics Consortium.* Estimation of the warfarin dose with clinical and pharmacogenetic data. *New Engl J Med* 2009; 360(8):753-764. ****Cavallari LH, author and data contributor**. PMID: 19228618. PMCID: PMC2722908
19. **Cavallari LH**, Aston JL, Momary KM, Shapiro NL, Patel SR, Nutescu EA. Predictors of unstable anticoagulation in African Americans. *J Thromb Thrombolysis* 2009;27(4):430-437. PMID 18563532.
20. Momary KM, Shapiro NL, Brace LD, Shord SS, Grossi E, Viana MA, Helgason CM, Nutescu EA, **Cavallari LH**. Influence of cyclooxygenase-1 genotype on *ex-vivo* aspirin response in patients at risk for stroke. *Cerebrovascular Dis* 2009;27(6):585-593. PMID 19390185.
21. Shord SS, **Cavallari LH**, Gao W, Jeong HY, Deyo K, Patel SR, Camp JR, Labott SM, Molokie RE. The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. *Eur J Clin Pharm* 2009;65(7):651-658. PMID 19357842.
22. Nochowitz B, Shapiro NL, Nutescu EA, **Cavallari LH**. Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population. *Ann Pharmacother* 2009;43(7):1165-1172. PMID 19549747.
23. **Cavallari LH**, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. *Pharmacotherapy* 2010;30(1):1-9. PMID 20030467. **Included in the NIH based Genetic Association Database (<http://geneticassociationdb.nih.gov>; records 574145 and 593486).**
24. Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, **Cavallari LH**, Ridker PM, Grice GR, Miller RD, Gage BF. A polymorphism in the *VKORC1* regulator calumenin predicts higher warfarin dose

- requirements in African Americans. *Clin Pharmacol Ther* 2010;87(4):445-451. PMID: 20200517. PMCID: PMC2928561
25. **Cavallari LH**, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA. Genetic and clinical predictors of warfarin dose requirements in African Americans. *Clin Pharmacol Ther* 2010;87(4):459-464. PMID: 20072124.
26. Limdi NA, Wadelius M, **Cavallari L**, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single *VKORC1* polymorphism is predictive of dose across 3 racial groups. *Blood* 2010;115(18):3827-3834. PMID: 20203262. PMCID: PMC2865873.
27. Limdi NA, Limdi MA, **Cavallari L**, Anderson AM, Crowley MR, Baird MF, Allon M, Beasley TM, Warfarin dosing in patients with impaired kidney function. *Am J Kidney Dis* 2010;56(5):823-831. PMID: 20709439. PMCID:PMC2963672
28. Perera MA, Gamazon E, **Cavallari LH**, Patel SR, Poindexter S, Kittles RA, Nicolae, D, Cox NJ. The missing association: sequencing-based discovery of novel SNPs in *VKORC1* and *CYP2C9* that affect warfarin dose in African Americans. *Clin Pharmacol Ther* 2011;89(3):408-415. PMID: 21270790. PMCID:PMC3625373
29. **Cavallari LH**, Momary KM, Patel SR, Shapiro NL, Nutescu EA, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics. *Blood Cells Mol Dis* 2011;46(2):147-150. PMID: 21185752.
30. Cochran KA, **Cavallari LH**, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. *Ther Drug Monit* 2011;33(4):433-438. PMID: 21743381. PMCID: PMC3212440
31. **Cavallari LH**, Butler C, Langaee TY, Wardak N, Patel SR, Viana MA, Shapiro NL, Nutescu EA. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. *Pharmacotherapy* 2011;31(8):785-792. PMID: 21923605.
32. **Cavallari LH**, Perera M, Wadelius M, Deloukas P, Taube G, Patel SR, Aquino-Michaels K, Viana MA, Shapiro NL, Nutescu EA. Association of the *GGCX* (CAA)_{16/17} repeat polymorphism with higher warfarin dose requirements in African Americans. *Pharmacogenet Genomics* 2012;22(2):152-158. PMID: 22158446. PMCID: PMC3261355. **Curators' favorite paper, Pharmacogenomics Knowledge Base (PharmGKB), December 2011.**
33. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, **Cavallari LH**. Decreased warfarin clearance associated with the *CYP2C9* R150H (*8) polymorphism. *Clin Pharmacol Ther* 2012;91(4):660-665. PMID: 22378156. ****Referenced in the Human Cytochrome P450 (CYP) Allele Nomenclature Database (www.cypalleles.ki.se).**
34. Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, **Cavallari LH**, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, Langaee T, Siguret V, Lorient MA, Sagreiya H, Altman RB, Shahin MH,

- Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C. Impact of the *CYP4F2* p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. *Clin Pharmacol Ther* 2012;92(6):746-756. PMID: 23132553.
35. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, **Cavallari LH**. Effect of *NQO1* and *CYP4F2* genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. *Pharmacogenomics* 2012;13(16):1925-1935. PMID: 23215885. PMCID: PMC3586586.
36. **Cavallari LH**, Vaynshteyn D, Freeman KM, Wang D, Perera MA, Takahashi H, Drozda K, Patel SR, Jeong H. *CYP2C9* promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in *CYP2C9**8-mediated effects. *Pharmacogenet Genomics* 2013 Apr;23(4):228-231. PMID: 23376925. PMCID: PMC3629689.
37. Shahin MH, **Cavallari LH**, Perera MA, Khalifa SI, Misher A, Langae T, Patel S, Perry K, Meltzer DO, McLeod HL, Johnson JA. *VKORC1* Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. *Thromb Haemost* 2013 Jun;109(6):1045-1050. PMID: 23571513. PMCID: PMC3712827.
38. Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo V, Progar K, Shah, E, Stamos TD, Wing C, Garcia JGN, Kittles R, **Cavallari LH**. Association of aldosterone synthase polymorphism (*CYP11B2* -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. *PLoS One* 2013 Jul 30;8(7):e71268, 1-10. PMCID:PMC3728110
39. Perera MA,* **Cavallari LH**,* Limdi NA,* Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langae TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. *Lancet* 2013 Aug; 382 (9894): 790-796. ***Contributed equally to the writing of this paper.**
40. Vardeny O, **Cavallari LH**, Claggett B, Desai AS, Anand I, Rossignol P, Zannad, F, Pitt B, Solomon SD. Race influences the safety and efficacy of spironolactone in severe heart failure. *Circ Heart Fail* 2013 Sept;6(5):970-976. PMID 23940307.
41. Drozda K, Labinov Y, Jiang, R, Thomas MR, Wong SS, Patel SR, Nutescu EA, **Cavallari LH**. A pharmacogenetics service experience for pharmacy students, residents, and fellows. *Am J Pharm Ed* 2013 Oct;77(8):175. PMID 24159216. PMCID:PMC3806959
42. Daneshjou R, Tatonetti NP, Karczewski KJ, Sagreiya H, Bourgeois S, Drozda K, Burmester JK, Tsunoda T, Nakamura Y, Kubo M, Tector M, Limdi NA, **Cavallari LH**, Perera M, Johnson JA, Klein TE, Altman RB. Pathway analysis of genome-wide data improves warfarin dose prediction. *BMC Genomics* 2013;14 Suppl 3:S11. PMID: 23819817. PMCID:PMC3829086.

43. Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, Desai AA, Duarte JD, Gordeuk V, Peace D, Kadkol SS, Dodge C, Saraf S, Garofalo J, Krishnan JA, Garcia JGN, **Cavallari LH**. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. *Pharmacotherapy* 2013 Nov;33(11): 1156-1164. PMID: 23864527. PMCID:PMC3985126.
44. Patel HN, Ursan ID, Zueger PM, **Cavallari LH**, Pickard AS. Stakeholder views on pharmacogenomic testing. *Pharmacotherapy* 2014 Feb;34(2):151-65. PMID: 24167008.
45. Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson AH, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Nicolae D, **Cavallari LH**, Perera MA. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. *Pharmacogenomics J* 2014 Jun; 14(3):223-8. PMID: 24018621. PMCID: PMC4016191
46. Daneshjou R, Gamazon ER, Burkley B, **Cavallari LH**, Johnson JA, Klein TE, Limdi N, Hillenmyer S, Percha B, Karczewski KJ, Langae T, Patel SR, Bustamante CD, Altman RB, Perera MA. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. *Blood* 2014 Oct 2;124(14):2298-305. PMID: 25079360. PMCID: PMC4183989. **Curators' Paper of Interest, Pharmacogenomics Knowledge Base (PharmGKB), August 2014.**
47. Patel SR, Langae TY, Wong SS, **Cavallari LH**. Pyrosequencing of the *CYP2C9*-1766T>C polymorphism as a means of detecting the *CYP2C9**8 allele. *Pharmacogenomics* 2014 Sep; 15(13):1717-22. PMID 25410896.
48. Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, **Cavallari LH**. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. *Pharmacogenet Genomics* 2015 Feb;25(2):73-81. PMID 25461246. PMCID: PMC4280295. **Curators' Paper of Interest, Pharmacogenomics Knowledge Base (PharmGKB), December 2014.**
49. Nagai R, Ohara M, **Cavallari LH**, Drozda K, Patel SR, Nutescu EA, Perera MA, Hernandez W, Kaneko N, Hibiya M, Takahashi H. Factors influencing pharmacokinetics of warfarin in African Americans: implications for pharmacogenetic dosing algorithms. *Pharmacogenomics* 2015 Mar;16(3):217-25. PMID: 25712185.
50. Hernandez W, Aquino-Michaels K, Drozda K, Patel S, Jeong Y, Takahashi H, **Cavallari LH**, Perera MA. Novel single nucleotide polymorphism in *CYP2C9* is associated with changes in warfarin clearance and *CYP2C9* expression levels in African Americans. *Transl Res* 2015 Jun;165(6):651-7. PMID: 25499099. PMCID: PMC4433569.
51. Parra EJ, Botton MR, Perini JA, Krithika S, Bourgeois S, Johnson TA, Tsunoda T, Pirmohamed M, Wadelius M, Limdi NA, **Cavallari LH**, Burmester JK, Rettie AE, Klein TE, Johnson JA, Hutz MA, Suarez-Kurtz G. Genome-wide association study of warfarin maintenance dose in a Brazilian sample. *Pharmacogenomics* 2015 July;16(11):1253-63. PMID 26265036. PMCID: PMC4573240.
52. Mansour IN, Bress AP, Groo V, Ismail S, Wu G, Patel SR, Duarte JD, Kittles RA, Stamos TD, **Cavallari LH**. Circulating procollagen type III N-terminal peptide and mortality risk in African Americans with heart failure. *J Card Fail* 2016 Sep;22(9):692-9.

53. Weitzel KW, Alexander M, Bernhardt BA, Calman N, Carey DJ, **Cavallari LH**, Field JR, Hauser D, Junkins HA, Levin PA, Levy K, Madden EB, Manolio TA, Odgis J, Orlando LA, Pyeritz R, Wu RR, Shuldiner AR, Bottinger EP, Denny JC, Dexter PR, Flockhart DA, Horowitz CR, Johnson JA, Kimmel SE, Levy MA, Pollin TI, Ginsburg GS for the IGNITE Network. The IGNITE network: a model for genomic medicine implementation and research. *BMC Med Genomics* 2016 Jan;9(1):1. PMID: PMC4700677.
54. Hamadeh IS, Shahin MH, Lima SM, Oliveira F, Wilson L, Khalifa SI, Langae TY, Cooper-DeHoff R, **Cavallari LH**, Johnson JA. Impact of *GGCX*, *STX1B*, and *FPGS* polymorphisms on warfarin dose requirements in European-Americans and Egyptians. *Clin Transl Sci* 2016 Feb;9(1):36-42. PMID 26751406.
55. Hernandez W, Gamazon ER, Smithberger E, O'Brien TJ, Harralson AF, Tuck M, Barbour A, Kittles RA, **Cavallari LH**, Perera MA. Novel genetic predictors of venous thromboembolism risk in African Americans. *Blood* 2016 Apr;127(15):1923-9. PMID: PMC4832509.
56. Daneshjou R, **Cavallari LH**, Weeke PE, Karczewski KJ, Drozda K, Perera MA, Johnson JA, Klein TE, Bustamante CD, Roden DM, Shaffer C, Denny JC, Zehnder JL, Altman RB. Population-specific single nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans. *Mol Genet Genomic Med* 2016 Jun;4(5):513-20. PMID: PMC5023936.
57. Weitzel KW, McDonough CW, Eley AR, Burkley B, **Cavallari LH**, Johnson JA. Effects of using personal genotype data on student learning and attitudes in a pharmacogenomics course. *Am J Pharm Educ* 2016 Sep;80(7):122. PMID: PMC5066925.
58. Kubo K, Ohara M, Tachikawa M, **Cavallari LH**, Lee MT, Wen MS, Scordo MG, Nutescu EA, Perera MA, Miyajima A, Kaneko N, Pengo V, Padrini R, Chen YT, Takahashi H. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. *Pharmacogenomics J* 2016 Aug 9. [Epub ahead of print]. PMID: 27503578.
59. Takahashi H, Ohara M, Shibata S, Lee MT, **Cavallari LH**, Nutescu EA, Scordo MG, Pengo V, Padrini R, Atsuda K, Matsubara H, Chen YT, Echizen H. Correlations between the enantio- and regio-selective metabolisms of warfarin. *Pharmacogenomics* 2017 Jan;18(2):133-142. PMID 27995809.
60. Arwood MJ, Deng J, Drozda K, Pugach O, Nutescu EA, Schmidt S, Duarte JD, **Cavallari LH**. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: a proposal for a new pharmacogenetic dosing approach. *Clin Pharmacol Ther* 2016 Nov 5. [Epub ahead of print]. PMID: 28032893.
61. Langae T, Stauffer LA, Galloway C, Solayman M, **Cavallari LH**. Cross-validation of high-resolution melting analysis-based genotyping platform. *Genet Test Mol Biomarkers*. [In press].
62. Hernandez W, Gamazon ER, Aquino-Michaels K, Smithberger E, O'Brien TJ, Harralson AF, Tuck M, Barbour A, **Cavallari LH**, Perera MA. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. *J Thromb Haemost* 2017 [In press].

63. Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, **Cavallari LH**, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR for the Pharmacogenomics Research Network Translational Pharmacogenetics Program. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetics implementation across diverse healthcare systems. *Clin Pharmacol Ther*. [In press]
64. Johnson JA, Caudle K, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, **Cavallari LH**, Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. *Clin Pharmacol Ther*. [In press].
65. M Kansal, Mansour I, Sahar I, Wu G, Bress AP, Mirza O, Kim Y, Li Y, **Cavallari LH**, Stamos T. Left ventricular global longitudinal strain predicts mortality and heart failure admissions in African American patients. *Clin Cardiol* [In press].
66. **Cavallari LH**, Beitelshees A, Blake K, Dressler L, Duarte J, Elsey A, Eichmeyer J, Empey P, Franciosi J, Hicks J, Holmes A, Jeng L, Lee C, Lima J, Limdi N, Modlin J, Obeng A, Petry N, Pratt V, Skaar T, Tuteja S, Voora D, Wagner M, Weitzel K, Wilke R, Peterson J, Johnson J. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. *Clin Trans Sci* [In press].
67. Hamadeh IS, Klinker KP, Borgert SJ, Richards AM, Li W, Mangal N, Hiemenz JW, Schmidt S, Langae TY, Peloquin CA, Johnson JA, **Cavallari LH**. Impact of the *CYP2C19* genotype on voriconazole exposure in adults with invasive fungal infections. *Pharmacogenet Genomics* [In press].

Conference Proceeding

68. Sharabiani A, Darabi H, Bress A, **Cavallari L**, Nutescu E, Drozda K. Machine learning based prediction of warfarin optimal dosing for African American patients. *IEEE International Conference on Automation Science and Engineering 2013*; MoET4.4:623-628. DOI: 10.1109/CoASE.2013.6653999

Reviews, Case Reports, and Commentaries

69. **(Cavallari) Humma LM**. Prevention and treatment of drug-resistant tuberculosis. (Review) *Am J Health-Syst Pharm* 1996;53(19):2291-2298; quiz 2335-2336. PMID 8893067.
70. Solomon DK, Gorley DR, Brown JR, Gorley GA, **(Cavallari) Humma LM**. Technology assessment and the drug use process. (Review) *Am J Manag Care* 1999;5(2):220-229; quiz 230-232. PMID 10346517.
71. **(Cavallari) Humma LM**, Swims MP. Bupropion mimics a transient ischemic attack. (Case Report) *Ann Pharmacother* 1999;33(3):305-307. PMID 10200854.
72. **(Cavallari) Humma LM**. Predicting adverse drug reactions using pharmacogenetics. (Invited Review) *Clin Trend Pharm Practice*. 2001;15(8):104-123.

73. Johnson JA, **(Cavallari) Humma LM**. Pharmacogenetics of cardiovascular drugs. (Invited Review) *Brief Funct Genomic Proteomic* 2002;1(1): 66-79. PMID 15251067.
74. **(Cavallari) Humma LM**, Terra, SG. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. (Invited Review) *Am J Health Syst Pharm* 2002;59(13):1241-1252. ****Included in the NIH Genetic Association Database (<http://geneticassociationdb.nih.gov>), Record 123152.** PMID 12116890.
75. **(Cavallari) Humma LM**. Predicting drug response with pharmacogenomics. (Invited Review) *Applied Genomic Proteomic* 2002;1(3):151-168.
76. Southworth MR, **Cavallari LH**. New treatment option for heart failure patients: Eplerenone. (Invited Review). *J Cardiovasc Nurs* 2004;19(6):390-395. PMID 15529060.
77. Johnson JA, **Cavallari LH**. Cardiovascular Pharmacogenomics. (Invited Review) *Exp Physiol* 2005;90(3):283-289. ****One of Top 10 Most-Frequently-Read Articles in *Exp Physiol* during July 2005.** PMID 15778411.
78. **Cavallari LH**, Limdi NA. Warfarin pharmacogenomics. (Invited Review) *Curr Opin Mol Ther* 2009;11(3):243-251. PMID 19479657.
79. **Cavallari LH**, Momary KM. Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease (Invited Review). *Curr Treat Options Cardiovasc Med* 2009;11(3):191-200. PMID 19433014. ****Curated for the NIEHS-funded Comparative Toxicogenomics Database (<http://ctdbase.org>) April 2012.**
80. Aquilante CL, Beitelshees AL, **Cavallari LH**, Lee CR, Maciejewski S, Momary K, Vardeny O, Zineh I. Significant articles in the field of cardiovascular pharmacogenomics. (Invited review) *Pharmacotherapy* 2009;29(9):1110-1151.
81. **Cavallari LH**, Overholser BR, Anderson D, Boyce E, Buie L, Formea CM, Gallagher JC, Hayney MS, Oestreich J. Recommended basic science foundation necessary to prepare pharmacists to manage personalized pharmacotherapy. (Invited Commentary) *Pharmacotherapy* 2010;30(6):228e-235e.
82. Johnson JA, **Cavallari LH**, Beitelshees AL, Lewis JP, Shuldiner AR, Roden DM. Pharmacogenomics: application to the management of cardiovascular disease. (Invited Review). *Clin Pharmacol Ther* 2011;90(4):519-531. PMID: 21918509. PMCID: PMC3190669.
83. **Cavallari LH**, Jeong H, Bress A. Role of cytochrome P450 genotype in the steps toward personalized drug therapy. (Invited Review) *Pharmgenomics Pers Med* 2011;4:123-136. PMID: 23226058. PMCID: PMC3513224.
84. **Cavallari LH**, Shin J, Perera MA. The role of pharmacogenomics in the management of traditional and novel oral anticoagulants. (Invited Review) *Pharmacotherapy* 2011;31(12):1192-1207. PMID: 22122181. PMCID: PMC3655546.
85. **Cavallari LH**, Perera MA. The future of warfarin pharmacogenetics in under-represented minority groups. (Invited Review) *Future Cardiol* 2012;8(4):563-576. PMID: 22871196. PMCID: PMC3463230

86. **Cavallari LH**. Tailoring drug therapy based on genotype. (Invited Review) *J Pharm Practice* 2012;25(4):413-416. PMID: 22907842.
87. Johnson JA, **Cavallari LH**. Pharmacogenetics and cardiovascular disease – implications for personalized medicine. (Invited Review) *Pharmacol Rev* 2013 Jul;65(3):987-1009. PMID: 23686351. PMCID: PMC3698938.
88. **Cavallari LH**, Nutescu EA, Duarte J. Personalized medicine in cardiology: the time for genotype-guided therapy is now. (Invited Commentary) *Future Cardiol* 2013;9(4):459-464. PMID: 23834684.
89. Perera MA, **Cavallari LH**, Johnson JA. Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. (Invited macroscopy) *Clin Pharmacol Ther* 2014 Mar;95(3):242-4. PMID: 24548987. PMCID: PMC4131541.
90. Lee YM, Eggen J, Soni V, Drozda K, Nutescu EA, **Cavallari LH**. Warfarin dose requirements in a patient with the *CYP2C9*14* allele. (Case Report) *Pharmacogenomics* 2014 May;15(7):909-14. PMID: 24956244. PMCID: PMC4151614.
91. **Cavallari LH**, Nutescu EA. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. (Invited Commentary) *Clin Pharmacol Ther* 2014 Jul;96(1):22-4. PMID: 24942399.
92. Johnson JA, **Cavallari LH**. Warfarin Pharmacogenetics. (Invited Review) *Trends Cardiovasc Med* 2015 Jan;25(1):33-41. PMID 25282448. PMCID: PMC4278947. **Curators' paper of interest, Pharmacogenomics Knowledge Base (PharmGKB), October 2014.**
93. **Cavallari LH**, Duarte JD. Genes affecting warfarin response – interactive or additive? (Invited Commentary) *J Clin Pharmacol* 2015 Mar;55(3):258-60. PMID 25385663.
94. **Cavallari LH**, Weitzel K. Pharmacogenomics in cardiology – genetics and drug response: 10 years of progress. (Invited Commentary) *Future Cardiol* 2015 May;11(3):281-6. PMID: 26021633. PMCID: PMC4477265.
95. Arwood MJ, **Cavallari LH**, Duarte JD. Pharmacogenomics of hypertension and heart disease. (Invited Review) *Curr Hypertens Rep* 2015 Sept;17(9):586. PMCID: PMC4730880.
96. **Cavallari LH**, Mason DL. Cardiovascular pharmacogenomics – implications for patients with CKD. (Invited Review) *Adv Chronic Kidney Dis* 2016 Mar;23(2):82-90. PMCID: PMC4795471.
97. **Cavallari LH**, Lee CR, Duarte JD, Nutescu EA, Weitzel KW, Stouffer GA, Johnson JA. Implementation of inpatient models of pharmacogenetics programs. (Invited Review) *Am J Health Syst Pharm* 2016 Dec;73(23):1944-54.
98. Arwood MJ, Chumnumwat S, **Cavallari LH**, Nutescu ED, Duarte JD. Implementing pharmacogenomics at your institution: establishment and overcoming implementation challenges. *Clin Transl Sci* 2016 May [Epub ahead of print] PMID: 27214750.

99. **Cavallari LH**, Obeng AO. Genetic determinants of P2Y₁₂ inhibitors and clinical implications. (Invited Review) *Interv Cardiol Clin* 2017 Jan;6(1):141-9. PMID: PMC5134418.
100. Deng J, Esteban VV, Rodriguez M, **Cavallari LH**, Schmidt S. Genotype-guided dosing of warfarin through modeling and simulation. (Invited Review). *Eur J Pharm Sci*. [In press].

Editorials and Letters

101. **(Cavallari) Humma LM**, Adenekan PL. Response to renin-angiotensin system antagonists in hypertensive blacks. (Letter to the Editor) *J Am Coll Cardiol* 2003;42(6):1141. PMID 13678945.
102. **Cavallari L**, Vaitkus P, Groo V. Hyperkalemia after the Publication of RALES. (Letter to the Editor) *New Engl J Med* 2004;351 (23):2448-2450. PMID 15580677.
103. **Cavallari LH**. Pharmacogenomics in heart failure: Individualizing therapy based on genotype. (Invited Editorial) *Future Cardiol* 2006;2(2):129-131. PMID 19804067.
104. **Cavallari LH**. β -adrenergic receptor pharmacogenetics. (Invited Editorial) *Future Cardiol* 2007;3(3):229-232. PMID 19804212.
105. Momary K, **Cavallari LH**. Clopidogrel and proton pump inhibitors – between a rock and a hard place. (Invited Editorial) *Pharmacotherapy* 2010;30(8):762-765. PMID: 20653351.
106. **Cavallari LH**, Schumock GT. Cost is not a barrier to implementing clopidogrel pharmacogenetics. (Invited Editorial) *Pharmacotherapy* 2012;32(4):299-303. PMID: 22461119.
107. **Cavallari LH**, Perera MA, Kittles RA. Genotype-guided dosing of vitamin K antagonists. (Letter to the Editor) *N Engl J Med* 2014 May;370(18):1763.
108. **Cavallari LH**, Duarte JD. Clopidogrel pharmacogenetics: from evidence to implementation. (Invited Editorial) *Future Cardiol* 2016 Sep;12(5):511-4.

Books

109. **(Cavallari) Humma LM**, Ellingrod VL, Kolesar JM. Drug Information Series - Pharmacogenomics Handbook. 1st ed. Lexi-Comp, Inc: Hudson, OH, 2003.
110. **Cavallari LH**, Ellingrod VL, Kolesar JM. Drug Information Series - Pharmacogenomics Handbook. 2nd edition. Lexi-Comp, Inc: Hudson, OH, 2005.
111. Lam YWF, **Cavallari LH** (eds). Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Elsevier Inc: Maryland Heights, MO. 2013. Companion materials available at booksite.elsevier.com/9780123919182.

Book Chapters

112. **(Cavallari) Humma LM**, Lam YWF. Pharmacogenetics: Genetic Contribution to Drug Response and an Introduction to Gene Therapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke

- GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 5th ed. McGraw Hill Companies, Inc: New York, 2002. pp. 55-67.
113. **Cavallari LH**. Cardiovascular Pharmacogenomics. In: Allen WL, Johnson JA, Knoell DL, Kolesar JM, McInerney JD, McLeod HL, Spencer HT, Tami JA (eds). Pharmacogenomic Applications in Patient Care. 1st ed. American College of Clinical Pharmacy: Kansas City, MO, 2004. pp. 495-532.
114. **Cavallari LH**, Shord SS. Pharmacogenomics. In: Schumock GT, Brundage DM, Chapman MM, et al (eds). Science and Practice of Pharmacotherapy, Book 5, Pharmacotherapy Self-Assessment Program. 5th ed. American College of Clinical Pharmacy: Kansas City, MO, 2005. pp. 189-214.
115. Johnson JA, **Cavallari LH**. Cardiovascular Pharmacogenomics. In: Raizada MK, Paton JFR, Katovich MJ, Kasparov S (eds). Cardiovascular Genomics: Gene Mining for Pharmacogenomics and Gene Therapy. Humana Press, Inc: Totawa NJ, 2005. pp. 71-94.
116. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 6th ed. McGraw-Hill Companies, Inc: New York, 2005. pp. 75-90.
117. **Cavallari LH**, DiDomenico RJ. Ischemic Heart Disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT (eds). Pharmacotherapy Principles & Practice. 1st ed. McGraw-Hill Companies, Inc: New York, 2007. pp. 63-82. ****This book received the American Medical Writers Association Distinguished 2008 Medical Book Healthcare Professionals Award.**
118. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 7th ed. McGraw-Hill Companies, Inc: New York, 2008. pp. 31-36.
119. Parker RB, Rogers JE, **Cavallari LH**. Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 7th ed. McGraw-Hill Companies, Inc: New York, 2008. pp. 173-216.
120. **Cavallari LH**, DiDomenico RJ. Ischemic Heart Disease. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT (eds). Pharmacotherapy Principles & Practice. 2nd ed. McGraw-Hill Companies, Inc: New York, 2010. pp. 109-129.
121. DiDomenico RJ, **Cavallari LH**. Stable Ischemic Heart Disease. In: Crouch M (ed). Cardiovascular Pharmacotherapy: A Point-of-Care Guide. 1st ed. American Society of Health-System Pharmacists, Inc: Bethesda, 2010. pp. 121-142.
122. Shin J, **Cavallari LH**. Warfarin Pharmacogenomics. In: Richardson MM, Hammond Chessman K, Chant C, Finks SW, Hemstreet BA, Hume AL, Hutchison LC, Karpiuk EL, McCollum M, Segarra-Newnham M, Sherer JR (eds). Science and Practice of Pharmacotherapy, Book 5, Pharmacotherapy Self-Assessment Program. 7th ed. American College of Clinical Pharmacy: Kansas City, 2011. pp. 51-67.
123. **Cavallari LH**, Peksa G, DiDomenico RJ. Ischemic Heart Disease. In: Katz MD, Matthias KR, Chisholm-Burns MA (eds). Pharmacotherapy Principles & Practice Study

- Guide: A Case Based Care Plan Approach. 1st ed. McGraw-Hill Companies, Inc: New York, 2011. pp. 31-34.
124. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 8th ed. McGraw-Hill Companies, Inc: New York, 2011. pp. 17. Complete chapter, learning objectives, and other resources available at www.pharmacotherapyonline.com.
125. Parker RB, **Cavallari LH**. Systolic Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 8th ed. McGraw-Hill Companies, Inc: New York, 2011. pp. 137-172.
126. **Cavallari LH**, DiDomenico RJ. Ischemic Heart Disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT (eds). Pharmacotherapy Principles & Practice. 3rd ed. McGraw-Hill Companies, Inc: New York, 2013. pp. 109-131.
127. Lam FY, **Cavallari LH**. Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications. In: Lam YWF, **Cavallari LH** (eds). Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Elsevier Inc: Maryland Heights, MO. 2013. pp. 1-44.
128. **Cavallari LH**, Klein TE, Huang SM. Governmental and Academic Efforts to Advance the Field of Pharmacogenomics. In: Lam YWF, **Cavallari LH** (eds). Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Elsevier Inc: Maryland Heights, MO. 2013. pp.63-88.
129. **Cavallari LH**, Momary KM. Pharmacogenetics in Cardiovascular Diseases. In: Lam YWF, **Cavallari LH** (eds). Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Elsevier Inc: Maryland Heights, MO. 2013. pp. 133-182.
130. **Cavallari LH**, Bress A, DiDomenico LH. Ischemic Heart Disease. In: Katz MD, Matthias KR, Chisholm-Burns MA (eds). Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach. 3rd ed. McGraw-Hill Education: New York, 2014. pp. 31-34.
131. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 9th ed. McGraw-Hill Companies, Inc: New York, 2014. eChapter available at www.mhpharmacotherapy.com
132. Parker RB, Nappi J, **Cavallari LH**. Chronic Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 9th ed. McGraw-Hill Companies, Inc: New York, 2014. pp. 85-122.
133. **Cavallari LH**, Shin JK. Pharmacogenetics of Anticoagulant Drugs. In: Johnson JA, Ellingrod VL, Kroetz DL, Kuo GM (eds). Pharmacogenomics: Applications to Patient Care. 3rd ed. American College of Clinical Pharmacy, Lenexa, 2015. Pp. 79-101
134. DiDomenico RJ, **Cavallari LH**. Ischemic Heart Disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT (eds). Pharmacotherapy Principles & Practice. 4th ed. McGraw-Hill Companies, Inc: New York, 2016. pp. 91-110.

135. Bress A, **Cavallari LH**, DiDomenico LH. Ischemic Heart Disease. In: Katz MD, Matthias KR, Chisholm-Burns MA (eds). *Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach*. 4th ed. McGraw-Hill Education: New York, 2016. Pp. 33-35..
136. Gaedigk A, Sangkuhl K, **Cavallari LH**. Pharmacogenetics and Genomics. In: Ye SQ (ed). *Big Data Analysis for Bioinformatics and Biomedical Discoveries*. Chapman & Hall/CRC Press: Boca Raton 2016. Pp. 179-200.
137. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach*. 10th ed. McGraw-Hill Companies, Inc: New York [In press].
138. Parker RB, Nappi J, **Cavallari LH**. Chronic Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach*. 10th ed. McGraw-Hill Companies, Inc: New York [In press].
139. **Cavallari LH**, Mosley SA, Johnson JA. Pharmacogenetics. In: Brody's Human Pharmacology.

Essays

140. **Cavallari LH**. Unanswered Questions: Pharmacogenomics. In: Russell PJ, Hertz PE, McMillan B (eds). *Biology: The Dynamic Science*. 2nd ed. Brooks/Cole, Cengage Learning, Inc, Belmont, CA. 2011. pp.411.
141. **Cavallari LH**. Unanswered Questions: Pharmacogenomics. In: Russell PJ, Hertz PE, McMillan B (eds). *Biology: The Dynamic Science*. 3rd ed. Brooks/Cole, Cengage Learning, Inc, Belmont, CA. 2014.

SELECT ABSTRACTS AND SCIENTIFIC PRESENTATIONS

99. Nutescu E, Duarte J, Cheng W, Sarangpur S, Gor D, Drozda K, Galanter W, Stamos T, Peace D, Garofalo J, Krishnan J, **Cavallari L**. Novel genotype guided personalized warfarin service improves outcomes in an ethnically diverse population. *Circulation* 2014;103:A16119. Poster presentation at the American Heart Association's Scientific Sessions. Chicago, IL. November 17, 2014.
100. **Cavallari LH**, Magvanjav O, Anderson RD, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Eley AR, Cooper-Dehoff RM, Weitzel KW, Clare-Salzler MJ, Nelson DR, Johnson JA. Fewer cardiovascular events after percutaneous coronary intervention with genotype-guided antiplatelet therapy: results from the UF Health Personalized Medicine Program. Moderated poster presentation at the Late-Breaking/Encore Abstract Poster Walk, American Society of Clinical Pharmacology and Therapeutics 2015 Annual Meeting. March 5, 2015. Full abstract published in the Final Meeting Program. Pp.170-171. #LBPW-4.
101. Kim K, Gor D, Walton SM, Galanter WL, Duarte J, Krishnan JA, Bauman JL, **Cavallari LH**, Nutescu EA. Novel pharmacist-guided pharmacogenetic service lowers warfarin-related

- hospitalizations. *Value in Health* 2015;18(3): A130. Poster presentation at the ISPOR 20th Annual International Meeting. May 19, 2015. Philadelphia, PA.
102. Manzoor B, Duarte J, Lee J, Galanter W, Walton S, Galanter N, Krishnan J, Bauman J, **Cavallari L**, Nutescu E. The impact of race on the association between a novel genotype-guided personalized warfarin service and clinical outcomes in an ethnically diverse population. *Value in Health* 2015;18(3):A131. Poster presentation at the ISPOR 20th Annual International Meeting. May 19, 2015. Philadelphia, PA.
103. Weitzel K, **Cavallari LH**, Elsey AR, Owusu Obeng A, Staley B, Ashton J, Vo T, Kong B, Ramos M, Higgins T, Cooper-DeHoff, R, Johnson JA. Development and implementation of pharmacist-led clinical pharmacogenetics services within a personalized medicine program. *Pharmacotherapy* 2015;35(11):e225 (#208). Poster presentation at the ACCP Global Conference on Clinical Pharmacy. October 18, 2015. San Francisco, CA.
104. **Cavallari LH**, Magvanjav O, Anderson RD, Gong Y, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Elsey AR, Allan RW, Starostik P, Cooper-DeHoff RM, Weitzel KW, Clare-Salzler MJ, Nelson DR, Johnson JA. Clinical implementation of *CYP2C19* genotype guided antiplatelet therapy reduces cardiovascular events after PCI. *Circulation* 2015;132(A11802). Poster presentation at the American Heart Association 2015 Scientific Sessions. November 9, 2015. Orlando, FL. Available through http://circ.ahajournals.org/content/132/Suppl_3/A11802.abstract?sid=cd6bc466-3451-41a8-8339-503e71988d82
105. De T, Nwanze N, Hernandez W, Smithberger E, Tuck M, O'Brien T, Kittles R, Duarte JD, Bourgeois S, **Cavallari L**, Perera M. Genome-wide association study to identify the genetic determinants of warfarin induced hemorrhagic complications in African Americans. *Clin Pharmacol Ther* 2016;99(S1):S73 (#PWII-2, PT-03). Poster walk presentation at the American Society for Clinical Pharmacology and Therapeutics 2016 Annual Meeting. San Diego, CA. March 9, 2016.
106. Hamadeh IS, Klinker KP, Borgert SJ, Richards AM, Li W, Ramos M, Mangal N, Hiemenz JW, Schmidt S, Peloquin CA, **Cavallari LH**, Johnson JA. Investigating the impact of *CYP2C19* ultrarapid metabolizer phenotype on voriconazole exposure in patients with invasive fungal infections. Poster presentation at the Late-Breaking/Encore Abstract Poster Walk, American Society of Clinical Pharmacology and Therapeutics 2016 Annual Meeting. San Diego, CA. March 11, 2016. Full abstract published in the Final Meeting Program.
107. Lima SM, Theofilogiannakos EK, Boudoulas KD, Shahin MH, Hamadeh IS, Langae TY, **Cavallari LH**, Pitsis AA, Boudoulas H. Genetic determination of collagen synthesis and degradation in patients with floppy mitral valve/mitral valve prolapse. *J Am Coll Cardiol*. 2016;67;13(S5):2221 (#1170-046). Poster presentation at the American College of Cardiology 65th Annual Scientific Session & Expo. Chicago, IL. April 4, 2016.
108. Bargal S, Kight J, de Oliveira F, Shahin M, Langae T, Gong Y, Hamadeh I, Cooper-DeHoff R, **Cavallari L**. Implications of polymorphisms in *BCKDK* and *GATA-4* genetic regions on stable warfarin dose in African Americans. *Pharmacotherapy* 2016;36(12):e267 (#250). Poster presentation at the American College of Clinical Pharmacy Annual Meeting. Hollywood, FL. October 23-26, 2016. ****Finalist for Best Student Poster.**

109. Duarte JD, Arwood MJ, Liko I, Mansour I, Nair V, Kansal M, Stamos T, **Cavallari LH**, Desai AA. Beta-blocker dose stratifies both mortality risk and circulating procollagen levels in African Americans with heart failure. *Circulation*. 2016;134:A11877. Poster presentation at the American Heart Association's Scientific Sessions. New Orleans, LA. November 15, 2016.
110. **Cavallari LH**, Denny JC, Lee CR, Beitelshes AL, Duarte JD, Kimmel SE, Voora D, McDonough CW, Gong Y, Wei WQ, Pratt VM, Chumnumwat S, Coons JC, Cooper-DeHoff RM, Dave CV, Dillon C, Hamadeh IS, Hines L, Howell LA, Jeng LJ, Lee YM, Skaar TC, Sriramoju VB, Stevenson JM, Vesely MR, Wake D, Kreutz RP, Stouffer GA, Wilke RA, Empey PE, Limdi NA, Roden DM, Shuldiner AR, Johnson JA, Peterson JF. Prospective Clinical Implementation of *CYP2C19*-Genotype Guided Antiplatelet Therapy After PCI: a Multi-Site Investigation of MACE Outcomes in a Real-World Setting. *Circulation* 2016;134:e711-712 (abstract #21050). Presented as a Late-Breaking Clinical Science Special Report: Precision Medicine on the Front Lines at the American Heart Association's Scientific Sessions 2016. New Orleans, LA. November 15, 2016.
111. Arwood MJ, Deng J, Drozda K, Nutescu EA, Schmidt S, Duarte JD, **Cavallari LH**. Clinical implementation of warfarin pharmacogenetics in a real-world setting: a proposal for a new pharmacogenetic dosing approach for diverse patient populations. *Clin Pharmacol Ther* 2017;101(S1):S5 (#PT-002). Poster presentation at the American Society of Clinical Pharmacology and Therapeutics 2017 Annual Meeting. March 15-18. Washington, DC.
****Selected as a Top Trainee Abstract.**

SELECT INVITED PRESENTATIONS

"Management of Cardiovascular Diseases in the Age of Genomics." Pharmacogenomics Curricular Track 2: Therapeutic Opportunities in the Age of Genomics, 2001 American College of Clinical Pharmacy Annual Meeting. Tampa, FL. October 2001.

"Genetic Influences of Responses to Cardiovascular Drugs." Program Title: Pharmacogenomics: The Future is Now! Current Applications in Clinical Practice. 2002 Midyear Clinical Meeting of the American Society of Health-System Pharmacists. Atlanta, GA. December 2002.

"The Impact of Pharmacogenetics on Drug Response and Applications to Disease Management." 40th Annual Meeting of the Drug Information Association. Washington, DC. June 15, 2004.

"Pharmacogenomics Applications in the Real World – Warfarin and Cardiovascular Pharmacogenomics." 2010 Spring Practice and Research Forum, American College of Clinical Pharmacy. Charlotte, NC. April 24, 2010.

"Cardiology I." Webinar. Pharmacogenomics Education™ Program (PharmGenEd): Bridging the Gap between Science and Practice. September 21, 2010.

"Cardiology II." Webinar. Pharmacogenomics Education™ Program (PharmGenEd): Bridging the Gap between Science and Practice. September 23, 2010.

“Pharmacogenetics: Clinical Applications & Implications for PharmD Programs.” Science Plenary, 2013 Annual Meeting of the American Association of Colleges of Pharmacy. Chicago, IL. July 15, 2013.

“Warfarin Pharmacogenetics – Evidence and Clinical Implementation.” Pharmacogenomics and Personalized Medicine: Progress in Clinical Implementation Symposium. 10th International Meeting of the Society for the Study of Xenobiotics. Toronto, Ontario, Canada. September 30, 2013.

“Clinical Pharmacogenetics - Focus on Cardiovascular Pharmacotherapy” PK/PD/Pharmacogenetics PRN Symposium entitled “Applying Pharmacogenetics to Patient Care.” 2013 American College of Clinical Pharmacy Annual Meeting, Albuquerque, New Mexico, October 14, 2013.

“African American Dosing Algorithms” as part of the “IWPC Update: Advancing Warfarin Pharmacogenomics,” Pharmacogenomics Research Network – Research in Progress Seminar series. November 8, 2013.

“Genomics in Heart Failure: Additive or Redundant.” SMP.301. Personalized Medicine: Pharmacogenomics & Metabolomics- Is That Your Final Answer? American Heart Association Scientific Sessions. Dallas, TX. November 17, 2013.

“Outcomes with a Warfarin Pharmacogenetics Consult Service.” Hot Topic at the Pharmacogenomics Research Network (PGRN) Scientific Meeting. Orlando, FL. April 2, 2014.

“Pharmacogenetic Implementation – Opportunities and Challenges.” For session entitled, “Advanced Applications of Molecular Diagnostics and Pharmacogenomics in Targeted Therapeutics.” American Association for Clinical Chemistry Annual Meeting and Clinical Laboratory Exposition. Chicago, IL. July 27, 2014.

“Cardiovascular Pharmacogenomics: Applications to Patient Care.” Balassone Lecture at the University of Maryland School of Pharmacy. October 6, 2014.

“Pharmacogenetics versus Traditional Strategies for Warfarin Dosing.” Session Title: Challenges and Opportunities in Personalized Medicine. American Heart Association Scientific Sessions. Chicago, IL. November 18, 2014.

“Implementation of a Pharmacogenomics Service into Clinical Practice.” How to Set Up a Clinical Pharmacogenomics Service: Advice from Established Services. American Society of Health-System Pharmacists 2014 Midyear Clinical Meeting and Exhibition. Anaheim, CA. December 7, 2014.

“Basic Pharmacogenomics for the Heart Failure Clinician.” 2015 Comprehensive Heart Failure Review. Heart Failure Society of America. Tampa, FL. October 23, 2015.

“Pharmacogenomics – From Evidence to Implementation.” Distinguished Lecturer, Endowed Chu Lectureship. Idaho State University College of Pharmacy. Meridian, ID. November 5, 2015.

“CYP2C19 Genotype Testing and Clopidogrel Dosing – Real World Experience and Case Examples.” Precision Medicine Intensive, American College of Cardiology 65th Annual Scientific Session & Expo. Chicago, IL. April 4, 2016.

“Screening for *CYP2C19* Variants in Patients Undergoing Cardiac Catheterization.” IGNITE (Implementing Genomics in Practice) Unifying the Evaluation and Implementation of Genomic Medicine. Bethesda, MD. August 18, 2016.

“Pharmacogenomics and Predictive-Prescribing: Are We There Yet?” 2016 American College of Clinical Pharmacy Annual Meeting. Hollywood, FL. October 23-26, 2016.

“Outcomes with *CYP2C19* Genotyping for Clopidogrel Response. Clinical Pharmacogenetics Implementation Consortium meeting. Washington, DC. March 15, 2017.

AWARDS AND HONORS

CRC Press Freshman Chemistry Award, Georgia Southern University, 1987

Kenneth L. Waters Pharmacy Scholarship, University of Georgia, 1989-1990

Rho Chi Certificate of Excellence, University of Georgia, 1991

Merck Award of Academic Excellence, University of Georgia, 1991

Fellow, American Foundation for Pharmaceutical Education for the Biomedical Research Sciences, University of Florida, 1999-2000.

Kenneth F. Finger Memorial Award for Excellence in Clinical Pharmacy Research, University of Florida, 2000

Winner, American College of Clinical Pharmacy 2000 Annual Meeting Best Student, Resident, Fellow Paper Award Competition

American Association of Colleges of Pharmacy-American Foundation for Pharmaceutical Education Pharmacy Faculty New Investigator, 2004

Teacher of the Year Honorable Mention Award from the Pharmacy Class of 2007, University of Illinois at Chicago, Academic year 2004-2005.

Teacher of the Year Nominee from the Pharmacy Class of 2008, University of Illinois at Chicago, Academic year 2005-2006.

Teacher of the Year Nominee from the Pharmacy Class of 2009, University of Illinois at Chicago, Academic year 2006-2007.

Hans Vahlteich Research Award, College of Pharmacy, University of Illinois at Chicago, 2007

Fellow, American College of Clinical Pharmacy, elected 2008

Best Paper, 2009 American College of Clinical Pharmacy and International Congress on Clinical Pharmacy

Kenneth F. Finger Fellow Alumni Lecturer Award, University of Florida, 2009

Member of the Month, April 2010, American Society of Clinical Pharmacology and Therapeutics

Elected Trustee, Research Institute, American College of Clinical Pharmacy, 2013 to 2016

Chair, Research Institute, American College of Clinical Pharmacy, 2014 to 2016

PROFESSIONAL SERVICE

American College of Clinical Pharmacy

- Course Instructor, Updates in Therapeutics: Pharmacotherapy Preparatory Course. “Outpatient Cardiology” and “Critical Care.” 2001 to 2003.
- Reviewer, Pharmacotherapy Self Assessment Program, 5th edition
- Reviewer, Pharmacogenomics: Applications to Patient Care, 2nd edition
- Reviewer, Cardiology PRN Grant Award, 2011, 2012, 2013
- Reviewer, Clinical Reasoning Series Professional Review – Pharmacogenomics
- Committee and Task Force Service

- 2002 to 2003: Member, Membership Committee
- 2003 to 2004: Subcommittee Chair, Program Committee
- 2004 to 2005: Member, Membership Committee
- 2005 to 2006: Member, Research Committee
- 2008 to 2009: Chair, Educational Affairs Committee
- 2009 to 2010: Member, Student CV Review Service
- 2009 to 2010: Member, FCCP Committee
- 2010 to 2011: Chair, Educational Affairs Committee
- 2011 to 2012: Member, Fellowship Credentialing Committee
- 2012 to 2014: Vice Chair, Fellowship Credentialing Committee
- 2014 to 2015: Secretary and Board Liaison, Research Affairs Committee
- ACCP Representative, Pharmacist Education in the Era of Genomic Medicine, a collaboration of multiple pharmacy organizations to develop competencies for pharmacists in genomics and pharmacogenomics, 2014
- Chair, Research Institute, 2014-2016
- Mentor, MERIT Program, 2015-2017

American Society of Clinical Pharmacology and Therapeutics

- Committee Service
 - 2007-2010, Education Committee member
- Abstract reviewer for 2010 meeting
- Mentor, ASCPT Mentoring Program, 2014-2016
- Mentoring Task Force, 2015-2016
- Member, Scientific Program Committee, 2016-2017

Clinical Pharmacogenetics Implementation Consortium

- Writing Committee, Update to Warfarin Guideline, Writing Committee
- Participant in 5 Phases of Delphi Process, Term Standardization for Clinical Pharmacogenetic Test Results

Pharmacogenomics Research Network

- Affiliate member, 2010-2015
- Member, 2016

Manuscript Reviewer: *American Journal of Cardiology, American Journal of Health-System Pharmacy, American Journal of Medical Genetics, Annals of Pharmacotherapy, Cardiovascular Therapeutics, Case Reports in Medicine, Circulation, Circulation-Cardiovascular Genetics, Cleveland Clinic Journal of Medicine, Clinical Chemistry, Clinical Chemistry and Laboratory Medicine, Clinical Medicine & Research, Clinical Pharmacokinetics, Clinical Pharmacology and Therapeutics, Clinical Research and Regulatory Affairs, Current Medical Research and Opinion, Expert Opinion on Pharmacotherapy, Expert Review of Precision Medicine and Drug Development, Frontiers in Pharmacology, Future Cardiology, JAMA, Journal of the American Pharmacists Association, Journal of Endovascular Therapy, Journal of Cardiovascular Pharmacology, Journal of Clinical Pharmacology, Journal of Community Genetics, Molecular Diagnosis & Therapy, Pharmacist Letter, Pharmacogenetics and Genomics, Pharmacogenomics, The Pharmacogenomics Journal, Pharmacotherapy, Puerto Rico Health Sciences Journal, Southern Medical Journal, Thrombosis, Thrombosis and Haemostasis*

Grant Review

10/2009 NIH CICS Study Section, ad hoc reviewer

02/2010 NIH CICS Study Section, ad hoc reviewer
02/2010 NIH Special Emphasis Panel on Microvascular Interactions, HP Study Section, ad hoc reviewer
10/2010 NIH SAT/BTSS Member Conflict Study Section, ad hoc reviewer
10/2010 Heart Research UK (HRUK), Translational Research Project Grants, ad hoc reviewer
06/2011 NIH CICS Study Section, ad hoc reviewer
12/2011 NIH ZRG1 CVRS-C(50), PAR10-238 ACCORD Ancillary Studies, Special Emphasis Panel, ad hoc reviewer
03/2012 American Heart Association Thrombosis 2 Study Section, Peer reviewer
10/2012 American Heart Association Vascular Wall, Lung and Thrombosis Clinical Committee, Peer reviewer
03/2013 American Heart Association, Vascular Wall Biology Committee, Peer reviewer
10/2013 American Heart Association, Vascular Wall Biology Clinical Committee, Peer reviewer
10/2014 American Heart Association, Lipids, Lung, Thrombosis, Vascular Endo, Vascular Wall Bio Clinical Committee, Peer reviewer
04/2015 American Heart Association, Vascular Wall Biology Clinical Committee, Peer reviewer
08/2015 NIH ZGM1 PPBC-9 PG Scientific Review Group, ad hoc reviewer
04/2016 American Heart Association, Lipids, Lung, Thrombosis, Vascular Wall Bio Clinical Committee, Peer reviewer
06/2016 NIH Nursing and Related Clinical Sciences (NRCS), ad hoc reviewer
10/2016 NIH Nursing and Related Clinical Sciences (NRCS), ad hoc reviewer

Associate Editor

- *PharmaNote Pharmacogenetics Corner*, Quarterly publication in the PharmaNote newsletter to provide information about pharmacogenetic testing for clinicians in community practice nationwide. Established 2015.

Editorial Board Member

- *Future Cardiology*, Future Medicine Ltd, London
- *Pharmacogenomics Handbook*, Lexi-Comp, Incorporated, Hudson, OH
- *Pharmacotherapy*, 2015 to present
- *Frontiers in Pharmacogenetics and Pharmacogenomics*, 2016 to present